Neurosurgeons may find themselves in a precarious situation, while unable to secure haemostasis following tumour resection. We report intraoperative use of tranexamic acid to secure complete haemostasis as rescue measure in intracranial meningioma resection in uncontrollable bleeding.

**Keywords:** Difficult hemostasis, intracranial meningioma, surgical resection, tranexamic acid

**INTRODUCTION**

The neurosurgical patients are at increased risk of bleeding following traumatic brain injury (TBI), subarachnoid hemorrhage (SAH) as well as during intracranial surgery. The role of tranexamic acid has been evaluated in patients with TBI and SAH. However, its role in intraoperative intracranial tumor bleeding has only been recently reported in a few patients. We report another case of giant bilateral falcaline meningioma in an adult patient, whereby an uncontrollable bleeding despite repeated attempts to achieve hemostasis was successfully managed with the use of tranexamic acid.

**CASE REPORT**

A 48-year-old female patient presented with abnormal behavior and urinary incontinence for 1 month. The patient was on oral telmisartan 20 mg once daily for hypertension. Magnetic resonance imaging scan of the brain revealed a large lobulated bilateral falcaline homogenous contrast-enhancing mass lesion measuring 6.5 cm × 6.0 cm × 6.5 cm [Figure 1a and b], with mass effect on adjacent structures and displacement of the bilateral anterior cerebral artery. Rest of the preoperative investigations was unremarkable. The bifrontal craniotomy was carried out under general anesthesia with invasive blood pressure and central venous pressure monitoring. During tumor resection, the patient had continuous bleeding, with fluctuating hemodynamic despite using oxidized cellulose polymer. Intravascular volume was maintained with crystalloid, colloid, and packed red cells transfusion. After 3 h of surgery and following loss of almost 2 L of blood, we decided to quit. However, it appeared difficult to achieve hemostasis. The bleeding continued from the tumor bed despite repeated attempts in spite using available hemostats during surgery to control it. There prevailed a situation of uncertainty. Based on our previous experience, it was decided to administer tranexamic acid at a dose of 10 mg/kg. Within 10 min of administration of tranexamic acid, there was a significant decrease in the bleeding from the tumor bed and in the next 20 min, we noted satisfactory hemostasis. This also coincided with the improvement in the hemodynamic profile of the patient and reduction of fluid to the maintenance dose. Postoperatively, the patient was shifted for elective ventilatory support and gradual reversal of neuromuscular blockade. The postoperative noncontrast computed tomography scan showed no major collections of blood in the operated field [Figure 2]. Subsequently, the patient was weaned off the ventilatory support and was discharged on the 10th postoperative day.

**DISCUSSION**

Tranexamic acid has shown to reduce blood transfusion requirement in various surgical procedures; however, the...
treatment effect may vary somewhat according to the type of surgery. Its use in neurosurgical patients has been restricted to few trials of TBI and SAH due to the fear of cerebral ischemia due to thrombosis and convulsion due to gamma-aminobutyric acid antagonism.\(^\text{[5,6]}\) Although theoretically some increased risk of cerebrovascular thrombosis might be expected, evidence from the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2 trial of tranexamic acid in bleeding trauma patients showed a statistically significant reduction in mortality with no increase in thromboembolic effects. Furthermore, there was a significant reduction in the risk of myocardial infarction in trauma patients who received tranexamic acid.\(^\text{[2]}\) Another report suggests no evidence in increased risk of either ischemic clinical manifestation or vasospasm after tranexamic acid use for the prevention of secondary bleed in patients with subdural hematoma.\(^\text{[1]}\)

The evidence for use of tranexamic acid to treat massive blood loss during intracranial surgery is weak.\(^\text{[4]}\) We used this as a desperate attempt to salvage the patient as multiple blood product transfusion, and surgical efforts to stop bleeding for a prolonged period was unrewarding. The present case report supports the role of tranexamic acid in patients who have significant intraoperative bleeding with difficulty in achieving hemostasis. However, this report is only a single personal experience and event might have occurred by chance. Only a prospective randomized trial can substantiate or refute the benefit of tranexamic acid use for controlling blood loss in this subset of patients.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: A prospective randomized study. J Neurosurg 2002;97:771-8.
2. Perel P, Al-Shahi Salman R, Kawahara T, Morris Z, Prieto-Merino D, Roberts I, et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant
Haemorrhage) intracranial bleeding study: The effect of tranexamic acid in traumatic brain injury – A nested randomised, placebo-controlled trial. Health Technol Assess 2012;16:iii-xii, 1-54.

3. Bhagat H, Kumar B, Garg N, Chhabra R. Tranexamic acid may be beneficial for difficult hemostasis following tumor resection in neurosurgical patients: A personal experience. Asian J Neurosurg 2017;12:309-10.

4. Bharath K, Bhagat H, Mohindra S. Use of tranexamic acid as a rescue measure to achieve hemostasis after massive blood loss in a pediatric neurosurgical patient. J Neurosurg Anesthesiol 2011;23:376-7.

5. Fodstad H, Forssell A, Liliequist B, Schannong M. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: A consecutive controlled clinical trial. Neurosurgery 1981;8:158-65.

6. Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid (A) receptor antagonistic effect. J Pharmacol Exp Ther 2002;301:168-73.